Menu
Search
|

Menu

Close
X

Neogenomics Inc NEO.OQ (NASDAQ Stock Exchange Capital Market)

13.66 USD
+0.00 (+0.00%)
As of Oct 22
chart
Previous Close 13.66
Open 13.80
Volume 60,842
3m Avg Volume 161,736
Today’s High 13.83
Today’s Low 13.45
52 Week High 15.57
52 Week Low 7.08
Shares Outstanding (mil) 79.39
Market Capitalization (mil) 876.44
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
131
FY17
251
FY16
244
FY15
100
EPS (USD)
FY18
0.038
FY17
-0.181
FY16
-0.391
FY15
-0.044
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
3.52
5.83
Price to Book (MRQ)
vs sector
5.19
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
55.61
17.18
LT Debt to Equity (MRQ)
vs sector
51.21
12.76
Return on Investment (TTM)
vs sector
-2.25
14.27
Return on Equity (TTM)
vs sector
-13.82
15.99

EXECUTIVE LEADERSHIP

Douglas VanOort
Chairman of the Board, Chief Executive Officer, Since 2009
Salary: $616,346.00
Bonus: --
George Cardoza
President - Pharma Services Division, Since 2018
Salary: $352,692.00
Bonus: --
Sharon Virag
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Robert Shovlin
President - Clinical Services Division, Since 2016
Salary: $350,000.00
Bonus: --
Steven Jones
Executive Vice President, Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Healthcare Facilities & Services
Address:

12701 Commonwealth Dr Ste 9
FORT MYERS   FL   33913-8626

Phone: +1941.9231949

NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

SPONSORED STORIES